Cargando…

Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma

Gemcitabine has high activity against nasopharyngeal carcinoma (NPC). The level of ribonucleotide reductase subunit M1 (RRM1) expression is closely related to the efficacy of gemcitabine on non-small cell lung cancer and pancreatic cancer. However, the expression of RRM1 and its association with sen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Li-Ping, Xue, Cong, Zhang, Jian-Wei, Hu, Zhi-Huang, Zhao, Yuan-Yuan, Zhang, Jing, Huang, Yan, Zhao, Hong-Yun, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sun Yat-sen University Cancer Center 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777452/ https://www.ncbi.nlm.nih.gov/pubmed/22692073 http://dx.doi.org/10.5732/cjc.012.10029

Ejemplares similares

Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
por: Zhang, Yuan, et al.
Publicado: (2019)

Is Gemcitabine and Cisplatin Induction Chemotherapy Superior in Locoregionally Advanced Nasopharyngeal Carcinoma?
por: Zheng, Wei, et al.
Publicado: (2015)

The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma
por: Li, Xiao‐Min, et al.
Publicado: (2022)

In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma
por: Xue, Cong, et al.
Publicado: (2016)

Gemcitabine and cisplatin regimen facilitates prognosis of advanced nasopharyngeal carcinoma
por: Li, Qiongxuan, et al.
Publicado: (2018)

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
por: Jørgensen, Charlotte LT, et al.
Publicado: (2013)

Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma
por: Zhang, Jian-Wei, et al.
Publicado: (2015)

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
por: Mlak, R., et al.
Publicado: (2015)

RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy
por: Dong, Song, et al.
Publicado: (2010)

Novel chimeric transcript RRM2-c2orf48 promotes metastasis in nasopharyngeal carcinoma
por: Han, Ping, et al.
Publicado: (2017)

RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine
por: Chen, Ying, et al.
Publicado: (2018)

MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy
por: Lu, Huimin, et al.
Publicado: (2019)

Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurrent penile squamous cell carcinoma
por: Liu, Jian-Ye, et al.
Publicado: (2013)

Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma
por: Li, Yin, et al.
Publicado: (2015)

Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma
por: Zhang, Jian, et al.
Publicado: (2018)

Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo
por: Xue, Cong, et al.
Publicado: (2016)

Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Hong, Shaodong, et al.
Publicado: (2016)

Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017)

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)

Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update
por: Jin, Ting, et al.
Publicado: (2018)

The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis
por: Fei, Qian, et al.
Publicado: (2021)

The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
por: Zhang, Jian-Wei, et al.
Publicado: (2014)

Anti‐epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma
por: Peng, Hao, et al.
Publicado: (2018)

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
por: Zhao, Yuan-Yuan, et al.
Publicado: (2014)

Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy
por: Cao, Cai-neng, et al.
Publicado: (2015)

Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers
por: Tao, Hao‐Yun, et al.
Publicado: (2022)

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yang, Jiangping, et al.
Publicado: (2020)

Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma
por: Zhao, Lina, et al.
Publicado: (2016)

Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma
por: Yang, Qiao, et al.
Publicado: (2022)

Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Li, Wen-Fei, et al.
Publicado: (2016)

Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens
por: Zheng, Li, et al.
Publicado: (2018)

Assessment of Response to Different Induction Chemotherapy Regimens in Locally Advanced Nasopharyngeal Carcinoma
por: Lian, Chen-Lu, et al.
Publicado: (2023)

A Kinome Screen Identifies Checkpoint Kinase 1 (CHK1) as a Sensitizer for RRM1-Dependent Gemcitabine Efficacy
por: Zhou, Jun, et al.
Publicado: (2013)

Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
por: Xia, Guanggai, et al.
Publicado: (2017)

Genetic Variations in Radiation and Chemotherapy Drug Action Pathways and Survival in locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy
por: Liu, Huai, et al.
Publicado: (2013)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
por: Liu, Tongxin, et al.
Publicado: (2018)

Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma
por: Guo, Rui, et al.
Publicado: (2016)

Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance
por: Lin, Mei, et al.
Publicado: (2023)

Pretreatment Diffusion-Weighted MRI Can Predict the Response to Neoadjuvant Chemotherapy in Patients with Nasopharyngeal Carcinoma
por: Zhang, Guo-Yi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_91iqd0a8khmakqujvvtttodr0t